Quanterix Corporation develops and commercializes ultra-sensitive biomarker tools for life sciences research and clinical testing. Its business includes Simoa instruments, assay kits, consumables, spatial biology systems, contract research services, and clinical laboratory testing through its Accelerator Laboratory and Lucent Diagnostics brand.
QTRX news commonly covers biomarker testing for cognitive disease, including blood-based Alzheimer’s disease panels, collaborations that connect Lucent Diagnostics tests with clinical and community workflows, and updates tied to operating results. Company developments also include shareholder voting matters, governance changes, capital-structure disclosures, and clinical or regulatory topics related to its diagnostic and research offerings.
Quanterix (NASDAQ: QTRX) highlighted a Nature study using its Simoa p-Tau 217 assay on a Norwegian cohort of 11,000+ individuals aged 58+. The study reports age-stratified Alzheimer’s Disease Neuropathological Changes (ADNC) rising from 10% at 58–69.9 to 64.9% in those >90, and finds 30.4% ADNC in people aged 70+, with 11.4% preclinical AD, 10.8% prodromal AD, and 7.4% AD dementia. Researchers state ~10% of the 70+ population meet current treatment eligibility. Results used a validated commercial p-Tau 217 kit on an automated HD-X analyzer, aiming to improve population-level prevalence estimates and planning for therapies and trials.
Quanterix (NASDAQ: QTRX) announced publication in the journal Brain of a landmark study showing a dual-biomarker blood-test approach for multiple sclerosis (MS). The research found serum GFAP levels were significantly associated with higher risk of Progression Independent of Relapse Activity (PIRA), while serum NfL continued to predict future relapses and acute inflammatory activity. The study used the automated HD-X and the Simoa Neurology 2-Plex B kit and leveraged large Simoa-derived normative databases from thousands of individuals. An online interpretive tool adjusts for age, sex, and BMI to enable individualized clinical interpretation and monitoring.
Quanterix (NASDAQ: QTRX) reported third-quarter 2025 results for the period ending September 30, 2025, with revenue of $40.2M, up 12.3% year-over-year, and GAAP gross margin 42.8% (adjusted gross margin 45.9%).
The company highlighted post‑Akoya integration progress, capturing $67M of cost synergies and projecting $85M annualized synergies and cash‑flow breakeven in 2026. Adjusted EBITDA loss was $11.9M; cash and equivalents totaled $138.1M with expected year‑end cash of ~$120M. 2025 revenue guidance reiterated at $130–$135M (pro forma $165–$170M); adjusted cash use expected $34–$38M.
Quanterix (NASDAQ: QTRX) will report third quarter 2025 financial results and host a conference call on Monday, November 10, 2025 at 4:30 p.m. ET. The company will release a press release with its Q3 2025 results after market close on November 10, 2025, posted on its website.
Investors can join the live call by dialing (800) 715-9871 or (646) 307-1963 with conference ID 3186071, or listen via live webcast on the Quanterix Investors News & Events page. An archived replay will be available on the company website for one year.
Quanterix (NASDAQ: QTRX) has achieved a significant milestone as its Accelerator Laboratory received a clinical laboratory permit from the New York State Department of Health (NYSDOH) in the Clinical Chemistry category. The lab is now CLIA-certified across all 50 states, enabling nationwide clinical testing and biomarker analysis.
The state-of-the-art facility utilizes Simoa® technology for ultra-sensitive protein biomarker detection and has developed over 100 custom assays, supporting 264+ global clinical trials across neurology, immunology/oncology, and infectious diseases. The lab's Simoa® NfL Laboratory Developed Test (LDT) received approval as part of the permitting process.
Additionally, the company announced the integration of Lucent Diagnostics brand under the Accelerator Laboratory, expanding its clinical and research biomarker testing capabilities.
Quanterix (NASDAQ: QTRX), a biomarker detection technology company, announced its participation in the Canaccord Genuity 45th Annual Growth Conference. The presentation is scheduled for Tuesday, August 12th, at 3:30 p.m. ET in Boston, Massachusetts.
The company's executive team will conduct the presentation and hold one-on-one meetings with institutional investors. Interested parties can access the live webcast through the Investors section of Quanterix's website, with a replay available for a limited time after the event.
Quanterix (NASDAQ: QTRX) reported Q2 2025 financial results, highlighting its recent acquisition of Akoya Biosciences. The company posted revenue of $24.5 million, down 29% year-over-year, with a GAAP gross margin of 46.2%. The quarter resulted in a net loss of $30.0 million.
Key developments include achieving 75% of their $85 million synergy and cost reduction target, launching new p-Tau assays for Alzheimer's research, and obtaining medical device registration approval in China. The company maintains $263.8 million in cash and equivalents, with adjusted cash usage of $2.6 million.
For full-year 2025, Quanterix expects revenues of $130-135 million, or $165-170 million on a pro forma basis including Akoya. The company projects achieving cash flow breakeven in 2026.
Quanterix (NASDAQ: QTRX), a biomarker detection technology company, has scheduled its second quarter 2025 financial results conference call for Thursday, August 7, 2025, at 4:30 p.m. ET. The company will release its Q2 2025 financial results after market close on the same day.
Investors can access the conference call by dialing (800) 715-9871 or (646) 307-1963 with conference ID 5591565. A live webcast will be available on the company's website, with an archived replay accessible for one year.
Quanterix (NASDAQ: QTRX), a biomarker detection company, has announced a cooperation agreement with Kent Lake Capital. The key terms include: appointment of a new independent director by December 1, 2025, through a joint search process involving both parties, plans to declassify the Board at the 2025 Annual Meeting, and adoption of a majority voting standard for uncontested director elections.
Kent Lake has agreed to withdraw its director nominations and support the Board's candidates, along with accepting standstill and voting commitments until 30 days before Quanterix's 2027 Annual Meeting nomination deadline. The agreement aims to maintain focus on company strategy and maximize benefits from the Akoya transaction.
Quanterix (NASDAQ: QTRX) has launched two first-to-market phospho-tau assays: p-Tau 205 and p-Tau 212 for Alzheimer's disease research. These novel assays, developed on the company's Simoa® platform, enable precise detection of tau phosphorylation sites associated with early-stage Alzheimer's disease.
The announcement coincides with the company's presence at AAIC 2025, where its Simoa® technology is featured in over 55 presentations. Following the recent Akoya Biosciences acquisition, Quanterix now combines fluid-based biomarker detection with spatial proteomics capabilities, offering researchers comprehensive tools for neurodegenerative disease research.